{
    "id": 18365,
    "fullName": "PTK2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PTK2 positive indicates the presence of the PTK2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 5747,
        "geneSymbol": "PTK2",
        "terms": [
            "PTK2",
            "FADK",
            "FAK",
            "FAK1",
            "FRNK",
            "p125FAK",
            "pp125FAK",
            "PPP1R71"
        ]
    },
    "variant": "positive",
    "createDate": "02/22/2016",
    "updateDate": "05/27/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 8274,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor regression in colon cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 219,
                "name": "colon cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8273,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor regression in pancreatic cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4685,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a breast adenocarcinoma cell line treated with PHM16 demonstrated inhibition of Fak autophosphorylation and decreased cell proliferation in culture (PMID: 24657306).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3595,
                "therapyName": "PHM16",
                "synonyms": null
            },
            "indication": {
                "id": 3458,
                "name": "breast adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4667,
                    "pubMedId": 24657306,
                    "title": "Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24657306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4684,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a colorectal cancer cell line treated with PHM16 demonstrated inhibition of Fak autophosphorylation and decreased cell growth (PMID: 24657306).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3595,
                "therapyName": "PHM16",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4667,
                    "pubMedId": 24657306,
                    "title": "Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24657306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4698,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-00562271 re-sensitized chemoresistant prostate cancer cells to Taxotere (docetaxel) in culture, resulting in decreased phosphorylation of Ptk2 (Fak) and increased autophagy (PMID: 24194567).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3598,
                "therapyName": "Docetaxel + PF-00562271",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4671,
                    "pubMedId": 24194567,
                    "title": "Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24194567"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8275,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor suppression in glioblastoma cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8276,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor suppression in lung cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4686,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a prostate cancer cell line treated with PHM16 demonstrated inhibition of Fak autophosphorylation and decreased cell proliferation in culture (PMID: 24657306).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3595,
                "therapyName": "PHM16",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4667,
                    "pubMedId": 24657306,
                    "title": "Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24657306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8272,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor regression in breast cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4683,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a glioma cell line treated with PHM16 demonstrated inhibition of Fak autophosphorylation and decreased cell growth via cell cycle arrest in culture (PMID: 24657306).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 3595,
                "therapyName": "PHM16",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4667,
                    "pubMedId": 24657306,
                    "title": "Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24657306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8271,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-562271 inhibited PTK2 signaling, resulted in apoptosis and tumor regression in prostate cancer cell line xenograft models (PMID: 18339875).",
            "molecularProfile": {
                "id": 18706,
                "profileName": "PTK2 positive"
            },
            "therapy": {
                "id": 2087,
                "therapyName": "PF-562271",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1919,
                    "pubMedId": 18339875,
                    "title": "Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18339875"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18706,
            "profileName": "PTK2 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}